Health Care/Hospital

KANEKA UBIQUINOL™ AWARDED PRESTIGIOUS COMPLEMENTARY MEDICINES AUSTRALIA RAW MATERIAL SUPPLIER OF THE YEAR AWARD 2024

SYDNEY, Dec. 6, 2024 /PRNewswire/ -- Kaneka Ubiquinol™ has been awarded the covetedRaw Material Supplier of the Year Award 2024 at the Complementary Medicines Australia (CMA) Awards, held inSydney this evening.

2024-12-06 06:10 2044

IonOpticks' Custom Chromatography Column to Become Biognosys' Standard for High-Quality Proteomic Insights

MELBOURNE, Australia and ZURICH, Dec. 6, 2024 /PRNewswire/ -- Today,  IonOpticks, a world leading provider of chromatography solutions, and Biognosys, a global leader in mass spectrometry-based proteomics contract research services, announce a long-term supply agreement. Under the agreement, IonO...

2024-12-06 05:00 2053

AtomVie Global Radiopharma Appoints Dr. Pratibhash Chattopadhyay as Chief Business Officer to Accelerate Growth and Strengthen Leadership

HAMILTON, ON, Dec. 5, 2024 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, is pleased to announce the appointment of Dr. Pratibhash (Bosh) Chattopadhyay as Chief Business Officer. Dr. Chattopadhyay brings over 25 years of commercial and technical ...

2024-12-05 22:00 1051

Prenetics' IM8 and University of Oxford Begin Groundbreaking Space Experiment to Study Accelerated Aging and Longevity on the ISS with SpaceX, Supported by Space Applications Services

* Mission Launched via SpaceX CRS-31; Experiment Now Underway on the ISS * Collaboration Aims to Enhance Healthspan on Earth and Improve Astronaut Health in Space * IM8, a new premium supplements brand launched officially on November 18th on IM8health.com CHARLOTTE, N....

2024-12-05 21:30 2226

Field Medical's FieldForce™ Ablation System Earns FDA TAP Pilot Acceptance and Breakthrough Device Designation for the Treatment of Ventricular Tachycardia.

* First and only contact force pulsed field ablation (PFA) system engineered to revolutionize care for the hundreds of thousands at risk of death from ventricular tachycardia (VT). * FDA's TAP Pilot and Breakthrough Device Designation are awarded to medical devicesthat could provide more effe...

2024-12-05 21:03 1620

LifeSignals Receives EU MDR Certification for UbiqVue™ 2A Multiparameter System

Cloud-Based System, Featuring Wearable Biosensor with Chest-Based SpO2, Enables Active Patient Monitoring Across Hospital and Out-of-hospital Care Settings * Replaces time-consuming manual spot checking with continuous, near real-time active patient monitoring * Web-based system displays mult...

2024-12-05 20:00 1325

Cambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator Manufacturing

EAST RUTHERFORD, N.J., Dec. 5, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has signed an agreement with Eli Lilly and Company (Lilly) to deliver accelerated access to clinical development capabilities for Lilly...

2024-12-05 19:00 1426

NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis

MILAN, Dec. 5, 2024 /PRNewswire/ -- NTC, an international R&D focused pharmaceutical company headquartered inItaly, presents positive results from Phase II MIRAKLE study, a multicentre, randomized, blinded-assessor, phase II non-inferiority study evaluatingthe efficacy and tolerability of NTC014 ...

2024-12-05 19:00 1439

Cao Thang International Eye Hospital - Marking a footprint on the map of global ophthalmology

HO CHI MINH CITY, Vietnam, Dec. 5, 2024 /PRNewswire/ -- On November 10, 2024, Cao Thang International Eye Hospital was proudly certified to be an official membership with the World Association of Eye Hospitals (WAEH) at the 18th annual meeting which was held inChina. Cao Thang International Eye ...

2024-12-05 18:35 1889

SIMPLY HEALTH Appoints Aaron Kwok as Brand Ambassador for Active Probiotic Products

HONG KONG, Dec. 5, 2024 /PRNewswire/ -- SIMPLY HEALTH, a leading health supplement brand inHong Kong, is excited to announce the appointment of renowned singer and actorAaron Kwok as the brand ambassador for its "Active Probiotics" line. The announcement was made during a press conference held at...

2024-12-05 16:46 1839

Daewoong Pharmaceutical Captivates Global Experts at AMWC-SEA with 'Nabolift,' Redefining Toxin Treatments

- At "AMWC SEA 2024," one of the world's top three aesthetic medicine congresses, the Nabota booth attracted over 500 visitors. - Educated over 300 Thai physicians on the innovative "Nabolift" technique through the "Nabota Master Class (NMC)." - Established its position as a premium global brand...

2024-12-05 16:33 1576

MINISH Expands into Japan: Gaining Recognition as an Alternative to Orthodontic Treatment

TOKYO and SEOUL, South Korea, Dec. 5, 2024 /PRNewswire/ -- Japanese dentists who attended the Global MINISH Academy have announced plans to adopt MINISH. This shows the potential for the expansion of MINISH Members Clinics (MMCs) in Japan. There are currently 40 MMCs worldwide, with 38 in South Ko...

2024-12-05 14:00 1483

CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial

MELBOURNE, Australia, Dec. 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has successfully completed its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). Key...

2024-12-05 11:59 1559

Veeva Pulse Data Shows New Science Calls for More Connected Engagement

Synchronizing sales and marketing improves outcomes, yet 65% of field engagements are not SINGAPORE, Dec. 5, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today released its latestVeeva Pulse Field Trends Report

2024-12-05 09:00 1657

Former CSL CEO Paul Perreault appointed strategic adviser to Microbio

Establishing sepsis diagnostic InfectID™ as the new standard of care BRISBANE, Australia, Dec. 5, 2024 /PRNewswire/ -- Microbio Ltd, the Australian pathogen diagnostics company specialising in innovative molecular diagnostic solutions, has today announced the appointment ofPaul Perreault as a st...

2024-12-05 06:30 1786

Soprano Design & BT Win Smarter Workflows Award for NHS Solution

SOPRANO & BT TAKE HOME GOLD FOR CONVERSATIONAL AI SOLUTION REDUCING DID NOT ATTENDS & STREAMLINING CLINICAL PATHWAYS IN THE UK SYDNEY, Dec. 5, 2024 /PRNewswire/ -- Soprano Design, in partnership with BT, is thrilled to announce that its Patient Concierge solution has won the Smarter Workflows Aw...

2024-12-05 05:00 1599

LBB Specialties and Clariant Partner to Distribute High-Quality Pharmaceutical Grade PEGs for Ophthalmic Applications

NORWALK, Conn., Dec. 5, 2024 /PRNewswire/ -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, announced a strategic partnership with Clariant, a global leader in specialty chemical manufacturing. Through this collaboration, LBB Specialties will ...

2024-12-05 04:02 1356

CU Medicine invents a non-invasive technology for people with uninvestigated bowel symptoms

HONG KONG, Dec. 4, 2024 /PRNewswire/ -- The Chinese University of Hong Kong's Faculty of Medicine (CU Medicine) has, for the first time, discovered novel microbial signatures associated with inflammation of the gastrointestinal (GI) tract and transformed such signatures into clinically applicable...

2024-12-04 22:26 1797

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved mapping and dual energy ablation catheter

AUSTIN, Texas, Dec. 4, 2024 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first in the nation to use an all-in-one high-density mapping and dual energy ablation catheter for the treatment of persistent atria...

2024-12-04 10:07 1521

Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy

* Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission. * In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and ...

2024-12-04 09:10 2113
1 ... 9101112131415 ... 576